These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 26372487)

  • 1. Six-month outcomes of HIV-infected patients given short-course fluconazole therapy for asymptomatic cryptococcal antigenemia.
    Kapoor SW; Magambo KA; Kalluvya SE; Fitzgerald DW; Peck RN; Downs JA
    AIDS; 2015 Nov; 29(18):2473-8. PubMed ID: 26372487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reflexive Laboratory-Based Cryptococcal Antigen Screening and Preemptive Fluconazole Therapy for Cryptococcal Antigenemia in HIV-Infected Individuals With CD4 <100 Cells/µL: A Stepped-Wedge, Cluster-Randomized Trial.
    Meya DB; Kiragga AN; Nalintya E; Morawski BM; Rajasingham R; Park BJ; Mubiru A; Kaplan JE; Manabe YC; Boulware DR
    J Acquir Immune Defic Syndr; 2019 Feb; 80(2):182-189. PubMed ID: 30399034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and mortality of cryptococcal disease in adults with advanced HIV in an urban tertiary hospital in Sierra Leone: a prospective study.
    Lakoh S; Rickman H; Sesay M; Kenneh S; Burke R; Baldeh M; Jiba DF; Tejan YS; Boyle S; Koroma C; Deen GF; Beynon F
    BMC Infect Dis; 2020 Feb; 20(1):141. PubMed ID: 32059703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Prospective Evaluation of a Multisite Cryptococcal Screening and Treatment Program in HIV Clinics in Uganda.
    Nalintya E; Meya DB; Lofgren S; Huppler Hullsiek K; Boulware DR; Rajasingham R
    J Acquir Immune Defic Syndr; 2018 Jun; 78(2):231-238. PubMed ID: 29509588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings.
    Meya DB; Manabe YC; Castelnuovo B; Cook BA; Elbireer AM; Kambugu A; Kamya MR; Bohjanen PR; Boulware DR
    Clin Infect Dis; 2010 Aug; 51(4):448-55. PubMed ID: 20597693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Laboratory-Reflex Cryptococcal Antigen Screening Is Associated With a Survival Benefit in Tanzania.
    Faini D; Kalinjuma AV; Katende A; Mbwaji G; Mnzava D; Nyuri A; Glass TR; Furrer H; Hatz C; Boulware DR; Letang E
    J Acquir Immune Defic Syndr; 2019 Feb; 80(2):205-213. PubMed ID: 30422904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary prophylaxis of cryptococcal disease with fluconazole in HIV-positive Ugandan adults: a double-blind, randomised, placebo-controlled trial.
    Parkes-Ratanshi R; Wakeham K; Levin J; Namusoke D; Whitworth J; Coutinho A; Mugisha NK; Grosskurth H; Kamali A; Lalloo DG;
    Lancet Infect Dis; 2011 Dec; 11(12):933-41. PubMed ID: 21982529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cryptococcal antigenemia is associated with meningitis or death in HIV-infected adults with CD4 100-200 cells/mm
    Wykowski J; Galagan SR; Govere S; Wallis CL; Moosa MY; Celum C; Drain PK
    BMC Infect Dis; 2020 Jan; 20(1):61. PubMed ID: 31959112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of screening and treatment of cryptococcal antigenaemia among HIV-infected persons in Soweto, South Africa.
    Govender NP; Roy M; Mendes JF; Zulu TG; Chiller TM; Karstaedt AS
    HIV Med; 2015 Sep; 16(8):468-76. PubMed ID: 25689352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurocognitive function in HIV-infected persons with asymptomatic cryptococcal antigenemia: a comparison of three prospective cohorts.
    Montgomery MP; Nakasujja N; Morawski BM; Rajasingham R; Rhein J; Nalintya E; Williams DA; Huppler Hullsiek K; Kiragga A; Rolfes MA; Donahue Carlson R; Bahr NC; Birkenkamp KE; Manabe YC; Bohjanen PR; Kaplan JE; Kambugu A; Meya DB; Boulware DR;
    BMC Neurol; 2017 Jun; 17(1):110. PubMed ID: 28606065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda.
    Liechty CA; Solberg P; Were W; Ekwaru JP; Ransom RL; Weidle PJ; Downing R; Coutinho A; Mermin J
    Trop Med Int Health; 2007 Aug; 12(8):929-35. PubMed ID: 17697087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cryptococcal antigen prevalence in HIV-infected Tanzanians: a cross-sectional study and evaluation of a point-of-care lateral flow assay.
    Rugemalila J; Maro VP; Kapanda G; Ndaro AJ; Jarvis JN
    Trop Med Int Health; 2013 Sep; 18(9):1075-1079. PubMed ID: 23937699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Laboratory Reflex and Clinic-Based Point-of-Care Cryptococcal Antigen Screening for Preventing Meningitis and Mortality Among People Living With HIV.
    Drain PK; Galagan SR; Govere S; Krows M; Thulare H; Wallis CL; Gosnell BI; Moosa MY; Celum C; Bassett IV
    J Acquir Immune Defic Syndr; 2021 Aug; 87(5):1205-1213. PubMed ID: 33990495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implementation and operational research: Integrated pre-antiretroviral therapy screening and treatment for tuberculosis and cryptococcal antigenemia.
    Pac L; Horwitz MM; Namutebi AM; Auerbach BJ; Semeere A; Namulema T; Schwarz M; Bbosa R; Muruta A; Meya DB; Manabe YC
    J Acquir Immune Defic Syndr; 2015 Apr; 68(5):e69-76. PubMed ID: 25761234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cryptococcal Antigenemia in Immunocompromised Human Immunodeficiency Virus Patients in Rural Tanzania: A Preventable Cause of Early Mortality.
    Letang E; Müller MC; Ntamatungiro AJ; Kimera N; Faini D; Furrer H; Battegay M; Tanner M; Hatz C; Boulware DR; Glass TR
    Open Forum Infect Dis; 2015 Apr; 2(2):ofv046. PubMed ID: 26213690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No association of cryptococcal antigenemia with poor outcomes among antiretroviral therapy-experienced HIV-infected patients in Addis Ababa, Ethiopia.
    Smitson CC; Tenna A; Tsegaye M; Alemu AS; Fekade D; Aseffa A; Blumberg HM; Kempker RR
    PLoS One; 2014; 9(1):e85698. PubMed ID: 24465651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the initial 12 months of a routine cryptococcal antigen screening program in reduction of HIV-associated cryptococcal meningitis in Uganda.
    Enock K; Julius K; Griffith BC; Abila DB; Rutakingirwa MK; Kasibante J; Kandole KT; Kwizera R; Semeere A; Meya DB
    BMC Health Serv Res; 2022 Mar; 22(1):301. PubMed ID: 35246128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Universal screening of Tanzanian HIV-infected adult inpatients with the serum cryptococcal antigen to improve diagnosis and reduce mortality: an operational study.
    Wajanga BM; Kalluvya S; Downs JA; Johnson WD; Fitzgerald DW; Peck RN
    J Int AIDS Soc; 2011 Oct; 14():48. PubMed ID: 21988905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cryptococcal-related Mortality Despite Fluconazole Preemptive Treatment in a Cryptococcal Antigen Screen-and-Treat Program.
    Wake RM; Govender NP; Omar T; Nel C; Mazanderani AH; Karat AS; Ismail NA; Tiemessen CT; Jarvis JN; Harrison TS
    Clin Infect Dis; 2020 Apr; 70(8):1683-1690. PubMed ID: 31179488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inadequacy of High-Dose Fluconazole Monotherapy Among Cerebrospinal Fluid Cryptococcal Antigen (CrAg)-Positive Human Immunodeficiency Virus-Infected Persons in an Ethiopian CrAg Screening Program.
    Beyene T; Zewde AG; Balcha A; Hirpo B; Yitbarik T; Gebissa T; Rajasingham R; Boulware DR
    Clin Infect Dis; 2017 Nov; 65(12):2126-2129. PubMed ID: 29020172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.